INmune Bio Files for $250M Mixed Shelf Offering

Seeking AlphaMay 2 04:50

Inmune Bio's Promising INKmune Therapy and Strong Financials Merit a Buy Rating

TipRanksMay 1 01:45

INmune Bio Inc. Provides Update on Two Patients From the Phase 1b Alzheimer's Disease Trial Who Continue to Receive XPro Under Compassionate Use for Over Three Years

Boca Raton, Florida, April 30, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patient

GlobeNewswireApr 30 20:00

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune Natural Killer Cell Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology company focused on developing treatments that harness the patien

GlobeNewswireApr 29 20:00

Insiders Of INmune Bio Are Up 38% On Their US$714.9k Purchase

INmune Bio, Inc. (NASDAQ:INMB) insiders who bought shares over the past year were rewarded handsomely last week. The stock rose 35%, resulting in a US$61m rise in the company's market capitalisation,

Simply Wall StApr 27 21:26

INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Neuroinflammation

INmune Bio Says Remains On Track In Line With Prior Guidance To Complete Its Phase 2 Clinical Trial Involving The Use Of XPro For The Treatment Of Alzheimer's Disease In Patients With Biomarkers Of Ne

BenzingaApr 26 04:56